Vitamin B9 (calcium methyltetrahydrofolate).

This is the methyl folate trap, and it is the single most important pairing for this ingredient. Methionine synthase transfers the methyl group from 5-MTHF to homocysteine, regenerating tetrahydrofolate for the rest of the folate cycle. If B12 is inadequate the enzyme stalls, folate accumulates as 5-MTHF and the other folate-dependent reactions run short despite apparently adequate folate. Supplying methylfolate without B12 does not resolve that and can mask the haematological signal of low B12 while nerve involvement continues.

Homocysteine has two exits: remethylation back to methionine, which needs folate and B12, and transsulfuration to cystathionine and onward to cysteine, which needs B6. Loading only the remethylation arm leaves the other exit unsupported. This is why folate, B12 and B6 are given together in homocysteine-lowering protocols. Lowering a plasma homocysteine figure is a marker change, and marker changes are not outcomes.

Methylenetetrahydrofolate reductase holds an FAD cofactor, and the common C677T variant of the enzyme binds that FAD less tightly. Riboflavin status therefore affects MTHFR activity, more so in people carrying the variant. Since supplemental 5-MTHF is already the product of that reaction, it bypasses the step, which is precisely the argument for using this form. Riboflavin still matters for endogenous production from dietary folate.

There are two remethylation routes back to methionine. One uses 5-MTHF and B12 through methionine synthase and operates throughout the body. The other uses betaine through BHMT and is confined largely to liver and kidney. They are genuinely parallel, so supporting both gives redundancy where a single route is limiting. Betaine's homocysteine effect is well characterised and dose dependent.

Choline and folate are metabolically interlinked. Choline is oxidised to betaine, which donates a methyl group to homocysteine. When folate intake is low, more choline is diverted to this route, raising choline requirement. The traffic runs the other way too. Anyone loading one arm of one-carbon metabolism should account for the other.

The catalytic zinc in methionine synthase activates the homocysteine sulfur for attack on the methyl group carried by cobalamin. Without it the transfer does not proceed. This makes zinc structurally necessary for the reaction rather than a modulator of it, which is easy to overlook when the discussion focuses on folate and B12.

Folic acid is a synthetic oxidised form that must be reduced twice by dihydrofolate reductase before it becomes usable tetrahydrofolate. Human DHFR activity for this substrate is limited and varies widely between people, which is why unmetabolised folic acid appears in plasma at higher intakes. 5-MTHF enters the pool already reduced and methylated. Stacking both is common in practice and mostly reflects one being in a multivitamin while the other is taken separately.

The calcium salt and the glucosamine salt of 5-MTHF both release the same 5-methyltetrahydrofolate anion. They differ in hygroscopicity, crystalline stability and how they behave in a tablet, not in what reaches the circulation. Doubling up across two products simply adds the doses. Label figures should be checked, since some declare salt weight and others declare folate equivalents.

5-methyltetrahydrofolate oxidises readily to inactive breakdown products, which is a real problem in tablets, in gut contents and in blood samples. Ascorbate maintains a reducing environment that slows that degradation, which is why folate assays require ascorbate-stabilised samples. This is chemical protection of the molecule, not an effect on what folate does once it is in a cell.

One-carbon units do not appear from nowhere. Serine and glycine are the main donors, transferred onto tetrahydrofolate by serine hydroxymethyltransferase and by the glycine cleavage system. Supplying methylated folate at the downstream end without adequate one-carbon donors upstream limits what the cycle can do. This is basic pathway accounting and is routinely left out of folate discussions.

Methionine is converted to S-adenosylmethionine, used as a methyl donor, then to S-adenosylhomocysteine and homocysteine. A large methionine load therefore generates homocysteine that must be cleared through the folate-B12 route or the B6 transsulfuration route. The methionine loading test exploits exactly this. Anyone taking high-dose methionine should understand it increases demand on the folate cycle rather than sparing it.

SAMe is the universal methyl donor and it regulates its own supply. It inhibits MTHFR and activates cystathionine beta-synthase, pushing homocysteine toward transsulfuration when methyl groups are plentiful. Supplemental SAMe therefore acts on the same cycle from the far end and is not simply additive with folate. The regulatory loop is well characterised biochemistry.

Both key reductive steps in the folate cycle draw on NADPH. Niacin is the precursor to the NAD and NADP pool that supplies it. This is a background dependency rather than a targeted pairing, since NADPH supply is rarely the limiting factor in an ordinary diet. It is worth stating because it explains why folate metabolism is not isolated from general redox status.

Folate shortfall produces large red cells because DNA synthesis lags while the cytoplasm keeps maturing. Low iron status produces small pale ones because haemoglobin cannot be filled. When both are low the cell size indices can look deceptively normal because the two effects pull in opposite directions. This is a diagnostic trap worth knowing rather than a reason to combine them.

Calcium L-5-methyltetrahydrofolate carries calcium as its counter-ion, which stabilises the crystal and improves handling relative to the free acid. The calcium contributed at a typical folate dose is negligible against daily calcium intake. It is a formulation detail worth naming because people sometimes read the calcium in the ingredient name as a nutritional claim.